Advanced glycation end-products and the progress of diabetic vascular complications
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
15046548
Knihovny.cz E-resources
- MeSH
- Arteriosclerosis etiology physiopathology MeSH
- Diabetes Mellitus metabolism physiopathology MeSH
- Glycosylation MeSH
- Guanidines therapeutic use MeSH
- Hyperglycemia complications metabolism physiopathology MeSH
- Diabetes Complications * MeSH
- Humans MeSH
- Vascular Diseases drug therapy etiology MeSH
- Oxidative Stress physiology MeSH
- Peptides metabolism MeSH
- Glycation End Products, Advanced blood metabolism physiology MeSH
- Pyridoxamine therapeutic use MeSH
- Receptor for Advanced Glycation End Products MeSH
- Receptors, Immunologic physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Guanidines MeSH
- Peptides MeSH
- pimagedine MeSH Browser
- Glycation End Products, Advanced MeSH
- Pyridoxamine MeSH
- Receptor for Advanced Glycation End Products MeSH
- Receptors, Immunologic MeSH
Epidemiological studies have confirmed that hyperglycemia is the most important factor in the onset and progress of vascular complications, both in Type 1 and 2 diabetes mellitus. The formation of advanced glycation end-products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications including nephropathy, retinopathy, neuropathy and atherosclerosis. Recent studies have shown that increased formation of serum AGEs exists in diabetic children and adolescents with or without vascular complications. Furthermore, the presence of diabetic complications in children correlates with elevated serum AGEs. The level of serum AGEs could be considered as a marker of later developments of vascular complications in children with Type 1 and 2 diabetes mellitus. The careful metabolic monitoring of young diabetics together with monitoring of serum AGEs can provide useful information about impending AGE-related diabetic complications. It is becoming clear that anti-AGE strategies may play an important role in the treatment of young and older diabetic patients. Several potential drug candidates such as AGE inhibitors have been reported recently.